



PATIENT NAME : SNEHA WADKAR	RI	REF. DOCTOR : SELF			
	ACCESSION NO : 0002XC	013384	AGE/SEX	:34 Years	Female
SNEHA WADKAR	PATIENT ID : SNEHFO	5088929	DRAWN	:08/03/2024	11:58:23
	CLIENT PATIENT ID:		RECEIVED	:08/03/2024	12:00:15
	ABHA NO :		REPORTED	:09/03/2024	17:54:10
Test Report Status <u>Final</u>	Results	Biological I	Reference	e Interval L	Jnits

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE XRAY-CHEST

IMPRESSION

NO ABNORMALITY DETECTED

ECG

ECG

SINUS RHYTHM T ABNORMALITY IN ANTERIOR LEADS INFERIOR LEADS PROLONGED QT INTERVAL

### MEDICAL HISTORY

RELEVANT PRESENT HISTORY	FUNGLE SKI INFECTION ACIDITY WITH HEADACHE ON AND OFF
RELEVANT PAST HISTORY	OPERTAED RIGHT AXIAL LUMP IN 2018
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT
RELEVANT FAMILY HISTORY	HYPERTENSION
HISTORY OF MEDICATIONS	HORMONAL TREATEMET

# ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS	1.61	mts
WEIGHT IN KGS.	66.5	Kgs
BMI	26	BMI & Weight Status as follo <b>wg</b> /sqmts Below 18.5: Underweight 18.5 - 24.9: Normal

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE

NORMAL

Sexamark

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH Consultant Physician



25.0 - 29.9: Overweight 30.0 and Above: Obese



Page 1 Of 25







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF				
	ACCESSION N	0 : <b>0002XC013384</b>	AGE/SEX	:34 Years	Female
SNEHA WADKAR	PATIENT ID	: SNEHF05088929	DRAWN	:08/03/2024	11:58:23
	CLIENT PATIE	NT ID:	RECEIVED	:08/03/2024	12:00:15
	ABHA NO	:	REPORTED	:09/03/2024	17:54:10
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval 🛛	Jnits
GENERAL APPEARANCE / NUTRITIONAL	HEALTHY				

STATUS	
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
CAROTID PULSATION	NORMAL
TEMPERATURE	NORMAL
PULSE	88/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT
RESPIRATORY RATE	NORMAL

120/70 MM HG

# CARDIOVASCULAR SYSTEM

ΒP

	(SUPINE)
APEX BEAT	NORMAL
HEART SOUNDS	S1, S2 HEARD NORMALLY
MURMURS	ABSENT

# RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST MOVEMENTS OF CHEST BREATH SOUNDS QUALITY ADDED SOUNDS

NORMAL SYMMETRICAL VESICULAR (NORMAL) ABSENT

#### PER ABDOMEN

Sexamark

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 2 Of 25



Details

View

PERFORMED AT : Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

mm/Hg





				MC-5718	
PATIENT NAME : SNEHA WADKA	4R		<b>REF. DOCTOR :</b>	SELF	
		ACCESSION NO : 0002	XC013384	AGE/SEX : 34 Yea	ars Female
SNEHA WADKAR		PATIENT ID : SNEH	IF05088929		3/2024 11:58:23
		CLIENT PATIENT ID:		RECEIVED : 08/03/	
		ABHA NO :		REPORTED :09/03/	/2024 17:54:10
Test Report Status <u>Final</u>		Results	Biologica	I Reference Interv	val Units
APPEARANCE					
		NOT PALPABLE			
SPLEEN		NOT PALPABLE			
HERNIA		ABSENT			
CENTRAL NERVOUS SYSTEM					
HIGHER FUNCTIONS		NORMAL			
CRANIAL NERVES		NORMAL			
CEREBELLAR FUNCTIONS		NORMAL			
SENSORY SYSTEM		NORMAL			
MOTOR SYSTEM		NORMAL			
REFLEXES		NORMAL			
MUSCULOSKELETAL SYSTEM					
SPINE		NORMAL			
JOINTS		NORMAL			
BASIC EYE EXAMINATION					
CONJUNCTIVA		NORMAL			
EYELIDS		NORMAL			
EYE MOVEMENTS		NORMAL			
CORNEA		NORMAL			
DISTANT VISION RIGHT EYE WI GLASSES	IHOUT	WITHIN NORMAL LIM	IT (6/6)		
DISTANT VISION LEFT EYE WITH GLASSES	IOUT	WITHIN NORMAL LIM	IT (6/6)		
NEAR VISION RIGHT EYE WITHC GLASSES	UT	WITHIN NORMAL LIM	IT (N6)		
NEAR VISION LEFT EYE WITHOU	T GLASSES	WITHIN NORMAL LIM	IT (N6)		
A 4	N	I			
Straimarkaz	Starke				Page 3 Of 25
Dr. Swati Karmarkar, MD,DNB,DMRD	Dr. J N Shukla ,I Consultant Phys	-			

MD,DNB,DMRD Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





View Details







		MC-5718
PATIENT NAME : SNEHA WADKAR	REF. DC	OCTOR : SELF
SNEHA WADKAR	ACCESSION NO : 0002XC0133	
	PATIENT ID : SNEHF050889	
	CLIENT PATIENT ID: ABHA NO :	RECEIVED :08/03/2024 12:00:15 REPORTED :09/03/2024 17:54:10
		NEI ONIED 109/03/2024 17.34.10
Test Report Status <u>Final</u>	Results B	iological Reference Interval Units
COLOUR VISION	NORMAL (17/17)	
BASIC ENT EXAMINATION		
EXTERNAL EAR CANAL	NORMAL	
TYMPANIC MEMBRANE	NORMAL	
NOSE	NO ABNORMALITY DETECTED	
SINUSES	NORMAL	
THROAT	NO ABNORMALITY DETECTED	
TONSILS	NOT ENLARGED	
SUMMARY		
RELEVANT HISTORY	NOT SIGNIFICANT	
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT	
RELEVANT LAB INVESTIGATIONS	LOW HEMOGLOBIN (11.2)	
	RAISED WBC (10.31) RAISED ESR (21)	
	RAISED TRIGLYCERIDE (168)	
	LOW HDL CHOLESTEROL (38) RAISED T3 (302.0)	
	RAISED 13 (302.0) RAISED T4 (17.30)	
	LOW VITAMIN D (14.9)	
RELEVANT NON PATHOLOGY DIAGNOSTICS	USG- EARLY FATTY INFILTRATI	ON OF LIVER
	MAMMOGRAPHY CONCLUSION	
	NO FOCAL PARENCHYMAL LES BIRADS -1- NEGATIVE NO FIN	
REMARKS / RECOMMENDATIONS		WBC AND ESR, ALTRED BLOOD LIPID,
	RAISED T3/T4 LEVEL, LOW VI	TAMIN D
	ADV- MONITOR T3/T4 LEVEL F ADV- VITAMIN D SUPPLEMEN	
	FOLLOW UP WITH PHYSICIAN	HYPOTHYRODISUM ASAP
	FOLLOW UP WITH GYNOCOLO	GIST FOR FOR MAMMOGRAPHY REMARK

Sexamarka

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

Harkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician



View Report

Page 4 Of 25

1

View Details





PATIENT NAME : SNEHA WADKAR	<b>REF. DOCTOR :</b>	SELF
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15
	ABHA NO :	REPORTED :09/03/2024 17:54:10
Test Report Status Final	Results	Units

# MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN

- EARLY FATTY INFILTRATION OF LIVER.

### TMT OR ECHO

CLINICAL PROFILE 2 DECHO DONE : IMPRESSION. -GOOD LV SYSTOLIC FUNCTION AT REST. NO RWMA -LVEF 55-60%. -ALL VALVES STRUCTURALLY NORMAL. -NO EVIDENCE OF PE/CLOT/VEGETATION

<b>Interpretation(s)</b> MEDICAL HISTORY-THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Secamark

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 5 Of 25







PATIENT NAME : SNEHA WADKAR	REF. DOCTO	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female		
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23		
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15		
	ABHA NO :	REPORTED :09/03/2024 17:54:10		
Test Report Status Final	Results Biolog	gical Reference Interval Units		

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		/	
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	11.2 Low	12.0 - 15.0	g/dL	
	4.05		mil/ul	
RED BLOOD CELL (RBC) COUNT METHOD : FLUORESCENCE FLOW CYTOMETRY	4.05	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT	10.31 High	4.0 - 10.0	thou/µL	
METHOD : ELECTRICAL IMPEDANCE				
PLATELET COUNT	387	150 - 410	thou/µL	
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	34.5 Low	36 - 46	%	
		02.0 101.0	£I	
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	85.2	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.6	27.0 - 32.0	pg	
METHOD : CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN	32.5	31.5 - 34.5	g/dL	
CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER				
RED CELL DISTRIBUTION WIDTH (RDW)	13.7	11.6 - 14.0	%	
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM				
MENTZER INDEX	21.0			
MEAN PLATELET VOLUME (MPV)	9.5	6.8 - 10.9	fL	
METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	55	40 - 80	%	
METHOD : FLUORESCENCE FLOW CYTOMETRY				
LYMPHOCYTES	39	20 - 40	%	
METHOD : FLUORESCENCE FLOW CYTOMETRY MONOCYTES	4	2 - 10	%	
HONOCITES	т	2 10	<i>,</i> ,,	

keene

Dr. Sushant Chikane **Consultant Pathologist** 





View Details





0.02 - 0.10



PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF			
	ACCESSION NO : 0002XCC	<b>)13384</b> AGE/S	SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05	088929 DRAW	N :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEI	VED :08/03/2024 12:00:15	
	ABHA NO :	REPOF	RTED :09/03/2024 17:54:10	
Test Report Status <u>Final</u>	Results	Biological Refer	ence Interval Units	
METHOD : FLUORESCENCE FLOW CYTOMETRY				
EOSINOPHILS	1	1 - 6	%	
METHOD : FLUORESCENCE FLOW CYTOMETRY	4	0 1	0/	
BASOPHILS	1	0 - 1	%	
METHOD : FLUORESCENCE FLOW CYTOMETRY ABSOLUTE NEUTROPHIL COUNT	5.67	2.0 - 7.0	thou/µL	
METHOD : CALCULATED PARAMETER	5.67	2.0 - 7.0		
ABSOLUTE LYMPHOCYTE COUNT	4.02 High	1.0 - 3.0	thou/µL	
METHOD : CALCULATED PARAMETER	-			
ABSOLUTE MONOCYTE COUNT	0.41	0.2 - 1.0	thou/µL	
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT	0.10	0.02 - 0.50	thou/µL	

METHOD : CALCULATED PARAMETER ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED

<b>Interpretation(s)</b>

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

0.10

1.4

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.



Dr. Sushant Chikane **Consultant Pathologist** 





thou/µL

Vie<u>w Details</u>



Page 7 Of 25





PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
Test Report Status Final	Results Biological	Reference Interval Units	

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECK	JP BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (E	SR),EDTA		
E.S.R	21 High	0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOP	PED FLOW KINETIC ANALYSIS)		
GLYCOSYLATED HEMOGLOBIN(HBA1C), E BLOOD	DTA WHOLE		
HBA1C	5.1	Non-diabetic Adult Pre-diabetes 5.7 -	
		Diabetes diagnosis Therapeutic goals: Action suggested (ADA Guideline 20	<pre>&gt; or = 6.5 &lt; 7.0 : &gt; 8.0</pre>
METHOD : ION- EXCHANGE HPLC	<u> </u>		
ESTIMATED AVERAGE GLUCOSE(EAG)	99.7	< 116	mg/dL

<b>Interpretation(s)</b> ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-<b>TEST DESCRIPTION</b> :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. <b>TEST INTERPRETATION</b>

<b>Increase</b> in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR<b>(>100 mm/hour)</b> in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. <b>Decreased</b> in: Polycythermia vera, Sickle cell anemia

<b>LIMITATIONS</b>

<b>False elevated</b> ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia <b>False Decreased</b> : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr. Sushant Chikane **Consultant Pathologist** 

**PERFORMED AT :** 

Agilus Diagnostics Ltd

Mumbai, 400062 Maharashtra, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956



Page 8 Of 25



Vie<u>w Details</u>





**Biological Reference Interval** 



Units

**REF. DOCTOR : SELF PATIENT NAME : SNEHA WADKAR** ACCESSION NO : 0002XC013384 AGE/SEX :34 Years Female SNEHA WADKAR :08/03/2024 11:58:23 PATIENT ID : SNEHF05088929 DRAWN CLIENT PATIENT ID: RECEIVED : 08/03/2024 12:00:15 ABHA NO REPORTED :09/03/2024 17:54:10 :

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-<b>Used For</b>:

Results

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

Test Report Status

Identifying patients at increased risk for diabetes (prediabetes).

<u>Final</u>

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-

controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

<b>HbA1c Estimation can get affected due to :</b>
1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr. Sushant Chikane **Consultant Pathologist** 



Page 9 Of 25

View Report







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
Test Report Status Final	Results Biological	Reference Interval Units	

	IMMUNOHAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE			
ABO GROUP & RH TYPE, EDTA WHOLE E	BLOOD		
ABO GROUP METHOD : HAEMAGGLUTINATION (AUTOMATED)	0		
RH TYPE	POSITIVE		

METHOD : HAEMAGGLUTINATION (AUTOMATED)

<b>Interpretation(s)</b>

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane Consultant Pathologist



Page 10 Of 25

View Report

View Details







PATIENT NAME : SNEHA WADKAR		<b>REF. DOCTOR :</b>	SELF		
	ACCESSION NO : 000	2XC013384	AGE/SEX	:34 Years	Female
SNEHA WADKAR	PATIENT ID : SNE	HF05088929	DRAWN	:08/03/2024	11:58:23
	CLIENT PATIENT ID:		RECEIVED	:08/03/2024	12:00:15
	ABHA NO :		REPORTED	:09/03/2024	17:54:10
Test Report Status <u>Final</u>	Results	Biologica	l Referenc	e Interval 🛛	Jnits
	BIOCHEMISTRY				
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE				
GLUCOSE FASTING,FLUORIDE PLASMA					
FBS (FASTING BLOOD SUGAR)	98	Normal < Impaired		mg ucose:100 to	/dL
		125			
			mellitus: : n 1 occass	> = 126 (on	
			delines 20		
METHOD : SPECTROPHOTOMETRY HEXOKINASE					
GLUCOSE, POST-PRANDIAL, PLASMA					
PPRS(POST PRANDIAL BLOOD SUGAR)	119	Normal <	140	ma	/dl

PPBS(POST PRANDIAL BLOOD SUGAR)	119	Normal <140	mg/dL
		Impaired glucose	
		tolerance:140 to 199	
		Diabetes mellitus : $> = 200$	
		(on more than 1 occassion)	
		ADA guideline 2021	
METHOD : SPECTROPHOTOMETRY HEXOKINASE		-	

## LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	150	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHO	DLETSEROL OXIDASE, ESTERASE, PER	OXIDASE	
TRIGLYCERIDES	168 High	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLY	CEROL BLANK		
HDL CHOLESTEROL	38 Low	At Risk: < 40 Desirable: > or = 60	mg/dL
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMA	TIC COLORIMETRIC		
CHOLESTEROL LDL	78	Optimal : < 100 Near optimal/above optimal 100-129	mg/dL :

de la construcción de la constru pro

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab





Page 11 Of 25

-1

View Details







PATIENT NAME : SNEHA WADKAR REF. DOC			SELF		
	ACCESSION NO : 0002X	C013384	AGE/SEX	:34 Years	Female
SNEHA WADKAR	PATIENT ID : SNEHFO	)5088929	DRAWN	:08/03/2024	11:58:23
	CLIENT PATIENT ID:		RECEIVED	: 08/03/2024	12:00:15
	ABHA NO :		REPORTED	:09/03/2024	17:54:10
est Report Status <u>Final</u> Results		Biological	Reference	e Interval	Units
		Borderline High : 160 Very high	)-189	30-159	
METHOD : CALCULATED PARAMETER	110				/ II
NON HDL CHOLESTEROL	112	Desirable Above Des Borderline	sirable : 1	.30 -159	g/dL

		High : 190 - 219 Very high : > / = 220	
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	34.0 High	< or = 30.0 mg/dL	
CHOL/HDL RATIO	3.9	Low Risk : 3.3 - 4.4	
		Average Risk : 4.5 - 7.0	
		Moderate Risk : 7.1 - 11.0	
		High Risk : $> 11.0$	
METHOD : CALCULATED PARAMETER			
LDL/HDL RATIO	2.1	Desirable/Low Risk : 0.5 - 3.0	
		Borderline/Moderate Risk : 3.1	
		- 6.0	
		High Risk : > 6.0	
METHOD : CALCULATED PARAMETER			

## Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

<b>Risk Category</b>	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Factors

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

 $\mathcal{D}$ 

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab





View Report

Page 12 Of 25

View Details







Units

PATIENT NAME : SNEHA WADKAR **REF. DOCTOR : SELF** ACCESSION NO : 0002XC013384 AGE/SEX :34 Years Female SNEHA WADKAR PATIENT ID DRAWN :08/03/2024 11:58:23 : SNEHF05088929 CLIENT PATIENT ID: RECEIVED : 08/03/2024 12:00:15 ABHA NO REPORTED :09/03/2024 17:54:10 :

Test Report Status	Final	Results	<b>Biological Reference Interval</b>
l'obt hopoirt blatab	<u>i mai</u>	Rebuild	Biological Reference Interval

1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use 2. Family history of premature ASCVD 4. High blood pressure 5. Low HDL Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020. **Risk Group Treatment Goals Consider Drug Therapy** LDL-C (mg/dl) Non-HDL (mg/dl) LDL-C (mg/dl) Non-HDL (mg/dl) Extreme Risk Group Category A <50 (Optional goal < 80 (Optional goal >OR = 50>OR = 80< OR = 30) < OR = 60) < OR = 30Extreme Risk Group Category B < OR = 60> 30 >60>OR= 50 >OR= 80 Very High Risk <50 <80 High Risk <70 <100 >OR= 70 >OR=100 Moderate Risk <100 <130 >OR=100 >OR=130 Low Risk <100 <130 >OR = 130\*>OR=160

\*After an adequate non-pharmacological intervention for at least 3 months.

**References:** Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

#### LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.38	Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO MET	HOD		
BILIRUBIN, DIRECT	0.19	< or = 0.3	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIA	ΖΟΤΙΖΑΤΙΟΝ		
BILIRUBIN, INDIRECT	0.19	0.0 - 0.9	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	6.8	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REA	AGENT BLANK, SERUM BLANK		
ALBUMIN	4.1	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG	) - DYE BINDING		
GLOBULIN	2.8	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE	13	Upto 32	U/L
(AST/SGOT)			
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSE			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	13	Upto 33	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSP	PHATE ACTIVATION( P5P) - IFCC		
ALKALINE PHOSPHATASE	66	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	17	< 40	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC	- G-GLUTAMYL-CARBOXY-NITROANIL	IDE - IFCC	
LACTATE DEHYDROGENASE	127	< 223	U/L

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab



View Details



Page 13 Of 25







View Report

View Details

Patient Ref. No. 2000012266620

		MC-5718	
PATIENT NAME : SNEHA WAD	KAR	REF. DOCTOR : SELF	
	ACCESSION NO : 0002	XC013384 AGE/SEX	: 34 Years Female
SNEHA WADKAR	PATIENT ID SNEH	-05088929 DRAWN	:08/03/2024 11:58:23
	CLIENT PATIENT ID:	i	D :08/03/2024 12:00:15
	ABHA NO :	REPORTE	ED :09/03/2024 17:54:10
Test Report Status <u>Final</u>	Results	Biological Referen	ice Interval Units
METHOD : SPECTROPHOTOMETRY, LACTATE	E TO PYRUVATE - UV-IFCC		
BLOOD UREA NITROGEN (BUN	), SERUM		
BLOOD UREA NITROGEN	8	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, UREASE			-
CREATININE, SERUM			
CREATININE	0.64	0.60 - 1.10	mg/dL
METHOD : SPECTROPHOTOMETRY, JAFFE'S	ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDM	IS STANDARIZED	
BUN/CREAT RATIO			
BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	13.10	8 - 15	
URIC ACID, SERUM			
URIC ACID METHOD : SPECTROPHOTOMETRY, ENZYMA	4.2 NTIC COLORIMETRIC- URICASE	2.4 - 5.7	mg/dL
TOTAL DROTEIN CEDIM			
TOTAL PROTEIN, SERUM TOTAL PROTEIN	6.8	6.0 - 8.0	g/dL
	۵.۵ METRIC -BIURET, REAGENT BLANK, SERUM BLANK	0.0 - 0.0	g/uL
ALBUMIN, SERUM			
ALBUMIN	4.1	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOG			
, <b>∧∿~</b> `,	$\sim \alpha$		
Show.	J.		Page 14 Of 25
Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist	Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab		





PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID :SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
Test Report Status <u>Final</u>	Results Biologi	cal Reference Interval Units	

GLOBULIN GLOBULIN METHOD : CALCULATED PARAMETER	2.8	2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	136	136 - 145	mmol/L
METHOD : ISE INDIRECT POTASSIUM, SERUM	4.30	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT CHLORIDE, SERUM METHOD : ISE INDIRECT	101	98 - 106	mmol/L

#### Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens, hydrochlorothiazide,salicylates.

Sharm

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

Dr. Deepak Sanghavi **Chief Of Lab - Mumbai Reference** Lab



View Report

View Details







**REF. DOCTOR : SELF PATIENT NAME : SNEHA WADKAR** ACCESSION NO : 0002XC013384 AGE/SEX :34 Years Female SNEHA WADKAR :08/03/2024 11:58:23 PATIENT ID : SNEHF05088929 DRAWN CLIENT PATIENT ID: RECEIVED : 08/03/2024 12:00:15 REPORTED :09/03/2024 17:54:10 ABHA NO

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units

Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

<b>Interpretation(s)</b>

GLUCOSE FASTING, FLUORIDE PLASMA-<b>TEST DESCRIPTION</b>

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

<b>Increased in</b>:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.<b>Decreased in </b>:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

 <b>NOTE:</b>
 While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycamics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

treatment, Renal Giyosuna, Giycaemic index & response to rood consumed, Ammendary Trypogrycenia, Amendation Reported Amendation Reports Reported Amendation Reported A Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. <b>AST</b> is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

<b>ALP</b> is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

cb>GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine,spleen,heart, brain and seminal vesicles. The highest concentration is in the kidney,but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that

increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. <b>Total Protein</b> also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

<b>Albumin</b> is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-<br/>b>causes of Increased</br/>b levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) <br/>
 <b>Lower than normal level may be due to:</b>
 <br/>
 Myasthenia Gravis, Muscuophy<br/>
 URIC ACID, SERUM-<b>Causes of Increased levels:</b>
 -Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2<br/>
 DM,Metabolic syndrome <b>Causes of decreased levels</b>
 -Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab



Page 16 Of 25

View Report

Vie<u>w Details</u>







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF	
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15
	ABHA NO :	REPORTED :09/03/2024 17:54:10
	1	
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units

<b>Higher-than-normal levels may be due to:</b> Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.<br/><b>Lower-than-normal levels may be due to:</b> Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.<br/>ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. <br/><b>Low blood albumin levels (hypoalbuminemia) can be caused by:</br/>/b> Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

Dr. Deepak Sanghavi **Chief Of Lab - Mumbai Reference** Lab





View Report

Page 17 Of 25

View Details







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
		<u> </u>	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

C	LINICAL PATH - URINALYS	IS	
MEDI WHEEL FULL BODY HEALTH CHECKU	JP BELOW 40FEMALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
CHEMICAL EXAMINATION, URINE			
PH	6.0	4.6 - 8.0	
SPECIFIC GRAVITY	1.025	1.003 - 1.035	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NOT DETECTED		
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
FIGROGOUPIC EXAMINATION, UNINE			<i></i>

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	8-10	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM. (PH-DOUBLE INDICATOR,SP. GRAVITY-IONIC CONCEN,GLUCOSE-GOD/POD,PROTEIN- ERROR OF INDICATORS,KETONE-LEGAL'S,BLOOD- PEROXIDASE ACTIVITY-HB,BILIRUBIN-DIAZOTIZATION,UROBILINOGEN-DIAZOTIZATION,NITRITE-GRIESS,LEUKOCYTES- ESTERASES ACTIVITY)

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

Page 18 Of 25





Details







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR	: SELF
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15
	ABHA NO :	REPORTED :09/03/2024 17:54:10
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units

#### Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment	
Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



View Details



Page 19 Of 25







**PATIENT NAME : SNEHA WADKAR REF. DOCTOR : SELF** ACCESSION NO : 0002XC013384 AGE/SEX :34 Years Female SNEHA WADKAR PATIENT ID DRAWN :08/03/2024 11:58:23 : SNEHF05088929 CLIENT PATIENT ID: RECEIVED : 08/03/2024 12:00:15 ABHA NO REPORTED :09/03/2024 17:54:10 : **Test Report Status Final** Results **Biological Reference Interval** Units

	CYTOLOGY			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
PAPANICOLAOU SMEAR				
TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY			
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED (2CX- 6586)			
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY			
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.			
MICROSCOPY	THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, OCCASIONAL CLUSTERS OF ENDOCERVICAL CELLS IN THE MODERATE BACKGROUND OF POLYMORPHS.			
INTERPRETATION / RESULT	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY			
-	REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION (INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION)			

#### Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY, 2014, 3rd Edition) ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.

2) No cytologic evidence of hpv infection in the smears studied.

3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.

Dr.Nidhi Garg (Reg.No.MMC 2009/09/3278) Histopsthologist



Page 20 Of 25







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units	

#### **CLINICAL PATH - STOOL ANALYSIS**

## MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

#### MICROSCOPIC EXAMINATION, STOOL

REMARK

SAMPLE NOT RECEIVED

#### Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION		
Pus cells	Pus in the stool is an indication of infection		
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis		
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days.Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.		
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.		
Charcot-Leyden crystal	Parasitic diseases.		
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.		
Frank blood	Bleeding in the rectum or colon.		
Occult blood	Occult blood indicates upper GI bleeding.		
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.		
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.		
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.		
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.		

**ADDITIONAL STOOL TESTS :** 

Dr. Ekta Patil,MD Microbiologist



View Details



Page 21 Of 25

View Report





PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	
Test Report Status Final	Results Biologi	cal Reference Interval Units	

- 1. <u>Stool Culture</u>:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Fecal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. <u>Fecal Occult Blood Test(FOBT)</u>: This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. <u>Clostridium Difficile Toxin Assay</u>: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria,fungi,virus ,parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- 6. <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.



Dr. Ekta Patil,MD Microbiologist



Page 22 Of 25





View Report

View Details







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002XC013384	AGE/SEX : 34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088929	DRAWN :08/03/2024 11:58:23	
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15	
	ABHA NO :	REPORTED :09/03/2024 17:54:10	

Test Report Status <u>Final</u>

Results

**Biological Reference Interval** Units

#### **SPECIALISED CHEMISTRY - HORMONE** MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **THYROID PANEL, SERUM** 302.0 High ng/dL T3 Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0 METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY 17.30 High T4 Non-Pregnant Women µg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70 METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY NonPregnant Women 0.27- µIU/mL TSH (ULTRASENSITIVE) 2.710 4.20 Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000 METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

#### Comments

NOTE : RECHECKED FOR SERUM TOTAL T3 & TOTAL T4. PLEASE CORRELATE CLINICALLY. **Interpretation(s)** 

**Triiodothyronine T3**, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist



Page 23 Of 25

View Report

View Details







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF			
	ACCESSION NO : 0002XC013	<b>384</b> AGE/SEX :	34 Years Female	
SNEHA WADKAR	PATIENT ID : SNEHF05088	929 DRAWN :	08/03/2024 11:58:23	
	CLIENT PATIENT ID:		08/03/2024 12:00:15	
	ABHA NO :	REPORTED :	09/03/2024 17:54:10	
Test Report Status Final	Results	Biological Reference	Interval Units	

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> \*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





View Report

Page 24 Of 25

View Details







PATIENT NAME : SNEHA WADKAR	REF. DOCTOR : SELF			
	ACCESSION NO : 0002XC0133	B4 AGE/SEX : 34 Years Female		
SNEHA WADKAR	PATIENT ID : SNEHF0508892	29 DRAWN :08/03/2024 11:58:23		
	CLIENT PATIENT ID:	RECEIVED : 08/03/2024 12:00:15		
	ABHA NO :	REPORTED :09/03/2024 17:54:10		
Test Report Status <u>Final</u>	Results Bi	ological Reference Interval Units		

#### **CONDITIONS OF LABORATORY TESTING & REPORTING**

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

#### 4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

#### Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr. Deepak Sanghavi Chief Of Lab - Mumbai Reference Lab

Dr. Apeksha Sharma D.P.B,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





View Report

Page 25 Of 25

View Details

